Over the last few decades, neuroimaging techniques have advanced in the identification of structural, functional, and neurochemical brain abnormalities. Development of treatment using pharmaceutics and medical device has also highly advanced in the last decades. Neuroimaging offers non-invasive, quantitative, structural, high resolution, and functional evaluation of treatment effect using brain structural and functional methods. The field of neuroimaging in treatment evaluation can be applied in a variety of pathologies, including neurodegenerative diseases, stroke, traumatic brain injury, psychiatric disorders, autoimmune diseases, and oncology, and involves various imaging methods such as fMRI and phMRI (pharmacological MRI), EEG, PET, DTI, brain perfusion, (DSC, DCE and ASL), and structural imaging techniques. Imaging allows a non-invasive window to brain changes when treatment is applied.
Evaluating therapeutic effect is challenging; the changes may be subtle and heterogeneous across subjects. Imaging has the potential to promote understanding of mechanisms of brain treatment, can provide end points and surrogate markers in clinical trials, in the development of new therapies as well as new indications for existing ones.
Using imaging may allow prediction of individual response to treatment and help in personalized medicine, early diagnosis, treatment planning, and monitoring of disease progression. Most studies are showing the effect in the group level. For neuroimaging to be useful in a clinical setting it should be applied at the level of the individual rather than the group.
This Research Topic includes use of neuroimaging in clinical (in humans) and pre-clinical (animal) studies for evaluation of treatment effect, for neurodegenerative diseases, stroke, traumatic brain injury, psychiatric disorders, autoimmune diseases, and oncology, and other diseases.
We welcome manuscripts that include group analysis (randomized control trials) using existing imaging methods, combination of several methods, including structural and functional imaging, and new statistical methods to evaluate individual changes following treatment.
Treatment can be pharmaceutical, drug or food supply treatment or any medical device.
Imaging methods can be any functional or structural method, including MRI, PET, SPECT and EEG.
Topic Editor Efrat Sasson is employed by Arineta Ltd, is the founder and CEO of WiseImage. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Over the last few decades, neuroimaging techniques have advanced in the identification of structural, functional, and neurochemical brain abnormalities. Development of treatment using pharmaceutics and medical device has also highly advanced in the last decades. Neuroimaging offers non-invasive, quantitative, structural, high resolution, and functional evaluation of treatment effect using brain structural and functional methods. The field of neuroimaging in treatment evaluation can be applied in a variety of pathologies, including neurodegenerative diseases, stroke, traumatic brain injury, psychiatric disorders, autoimmune diseases, and oncology, and involves various imaging methods such as fMRI and phMRI (pharmacological MRI), EEG, PET, DTI, brain perfusion, (DSC, DCE and ASL), and structural imaging techniques. Imaging allows a non-invasive window to brain changes when treatment is applied.
Evaluating therapeutic effect is challenging; the changes may be subtle and heterogeneous across subjects. Imaging has the potential to promote understanding of mechanisms of brain treatment, can provide end points and surrogate markers in clinical trials, in the development of new therapies as well as new indications for existing ones.
Using imaging may allow prediction of individual response to treatment and help in personalized medicine, early diagnosis, treatment planning, and monitoring of disease progression. Most studies are showing the effect in the group level. For neuroimaging to be useful in a clinical setting it should be applied at the level of the individual rather than the group.
This Research Topic includes use of neuroimaging in clinical (in humans) and pre-clinical (animal) studies for evaluation of treatment effect, for neurodegenerative diseases, stroke, traumatic brain injury, psychiatric disorders, autoimmune diseases, and oncology, and other diseases.
We welcome manuscripts that include group analysis (randomized control trials) using existing imaging methods, combination of several methods, including structural and functional imaging, and new statistical methods to evaluate individual changes following treatment.
Treatment can be pharmaceutical, drug or food supply treatment or any medical device.
Imaging methods can be any functional or structural method, including MRI, PET, SPECT and EEG.
Topic Editor Efrat Sasson is employed by Arineta Ltd, is the founder and CEO of WiseImage. All other Topic Editors declare no competing interests with regards to the Research Topic subject.